hVIVO brings a broad range of capabilities and know how gained from delivering drug discovery and development testing services in respiratory diseases for over 20 years. Our services include a range of challenge studies, disease models, and other analytical services for early phase clinical development in respiratory diseases such as influenza, HRV, RSV and asthma.
By monitoring human response throughout the disease process, hVIVO human challenge studies and disease models provide both product testing outcomes and disease insights that enable you to:-
- Obtain superior clinical trial results: Conduct clinical studies in our purpose-built, controlled quarantine environment, promoting a superior study design and efficient trial process.
- Gain deeper disease understanding: Track virus induced disease symptom changes (e.g., exacerbation of existing respiratory diseases such as asthma) throughout its lifecycle to gain deeper insights into the disease process and host response, facilitating the identification and qualification of potential biomarkers and drug targets
- Deliver better drugs, faster: Determine efficacy sooner and guide future studies to streamline drug development